Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10064075 | 0.84 | ALDH1A1 (0.42) | ALDH1A1SRD5A1TP53TDP1TRPA1 | |
| SCHEMBL30360736 | 0.84 | ALDH1A1 (0.42) | ALDH1A1SRD5A1TP53TDP1TRPA1 | |
| SCHEMBL29935889 | 0.81 | ALDH1A1 (0.42) | ALDH1A1PIK3CDPRMT5WDR77DYRK1A | |
| SCHEMBL21382508 | 0.81 | ALDH1A1 (0.42) | ALDH1A1PIK3CDPRMT5WDR77DYRK1A | |
| SCHEMBL27165573 | 0.81 | ALDH1A1 (0.42) | ALDH1A1PIK3CDPRMT5WDR77DYRK1A | |
| SCHEMBL1697578 | 0.78 | ALDH1A1 (0.48) | ALDH1A1SRD5A1TP53TDP1TRPA1 | |
| SCHEMBL31122823 | 0.78 | ALDH1A1 (0.48) | ALDH1A1SRD5A1TP53TDP1TRPA1 | |
| SCHEMBL29475832 | 0.78 | ALDH1A1 (0.48) | ALDH1A1SRD5A1TP53TDP1TRPA1 | |
| SCHEMBL12015387 | 0.76 | ALDH1A1 (0.42) | ALDH1A1SRD5A1TP53TDP1TRPA1 | |
| SCHEMBL29935913 | 0.74 | ALDH1A1 (0.42) | ALDH1A1DYRK1ADYRK2DYRK1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324878-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-10-13 | — | — | US | disclosed |
| US-11365205-B2 | Imidazolidin-2-one compounds as PRMT5 modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-06-21 | — | — | US | disclosed |
| EP-3768670-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | Aurigene Discovery Technologies Limited (IN) | 2021-01-27 | — | — | EP | disclosed |
| US-20210002299-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-01-07 | — | — | US | disclosed |
| WO-2019180628-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365205-B2 | Imidazolidin-2-one compounds as PRMT5 modulators | PRMT5, PRMT1, PRMT7 | ALDH1A1 3027/4885SRD5A1 935/4885PIK3CD 2131/4885 |
| US-20210002299-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | PRMT5, PRMT1, PRMT7 | ALDH1A1 3027/4885SRD5A1 935/4885PIK3CD 2131/4885 |
| US-20220324878-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | PRMT5, PRMT1, PRMT7 | ALDH1A1 3027/4885SRD5A1 935/4885PIK3CD 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.